Clinical TrialsThe phase 3 Orbit study evaluating setrusumab in OI patients is designed with interim looks that could allow for early approval, increasing the potential for success.
Product PipelineThe current valuation of RARE assigns minimal value to the pipeline, creating an attractive risk/reward profile.
Revenue GrowthThe company has commercialized four products, which in aggregate generated $560 million in revenue in 2024, up 29% year-over-year.